Evidence map›Paper›PMID 40234359›Full record

ArticleJournal of general internal medicine2026

Prostate Cancer Screening Among Traditionally Underserved Populations at a Large Public Safety-Net Institution.

Hanna Zurl, Filippo Dagnino, Michelle Shabo, Rumel Mahmood, Benjamin G Allar, Boris Gershman, Lisa Weissman, Gezzer Ortega, Stephanie Hastings, Heidi J Rayala

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hanna ZurlDepartment of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Filippo DagninoDepartment of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Michelle ShaboDivision of Urology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Rumel MahmoodCambridge Health Alliance, Harvard Medical School, Cambridge, MA, USA.
Benjamin G AllarDepartment of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Boris GershmanDivision of Urology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Lisa WeissmanDepartment of Hematology/Oncology, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, USA.
Gezzer OrtegaCenter for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Stephanie HastingsDepartment of Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, USA.
Heidi J RayalaDivision of Urology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. hrayala@bidmc.harvard.edu.ORCID 0000-0003-4500-0939

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExisting literature underscores racial and sociodemographic disparities in prostate cancer screening (PCS) in the USA.

objectiveTo evaluate whether traditional PCS disparities are evident within a health safety-net institution tailored to support traditionally underserved populations.

designA retrospective cohort study using electronic health-record data was conducted at an urban safety-net institution.

participantsMale patients aged 51-70 years with a primary care provider (PCP) visit from 2018 to 2019 were included. MAIN MEASURES: The primary outcome was PCS, defined as receiving a Prostate Specific Antigen (PSA) blood test within the study period. Investigated patient characteristics included self-reported race and ethnicity, language, insurance, marital status, median household income, serious mental illness (SMI), substance use disorder (SUD), and family history of prostate cancer (PCa). Bivariate analyses using chi-squared tests and multivariable logistic regression analyses were performed to compare PCS rates between the groups. KEY

resultsThe cohort included 10,059 men, of which 40.4% had PCS. In total, 57.3% of the study population was of non-White race and 61.4% of non-North American/European ethnicity. A total of 31.2% had limited English proficiency (LEP), 17.8% had SMI, and 13.2% had SUD. In multivariable analysis of race, Black patients (OR 1.96, 95%CI 1.71-2.24, p < 0.001) and Hispanic patients (OR 1.51, 95%CI 1.3-1.76, p < 0.001) had significantly higher odds of PCS than White patients. Patients with LEP did not exhibit significantly lower screening rates than English-speaking patients (ORs 0.99-1.17).

conclusionsWithin a healthcare institution designed and implemented to meet the needs of underserved populations, traditional racial and sociodemographic disparities in PCS are not evident.

Indexed as

Early Detection of CancerHealthcare DisparitiesProstatic NeoplasmsSafety-net ProvidersVulnerable PopulationsAgedBlack or African AmericanCohort StudiesHispanic or LatinoHumansMaleMiddle AgedProstate-Specific AntigenRetrospective StudiesSocioeconomic Disparities in HealthWhiteProstate-Specific AntigenProstate cancer screeningPSARace/ethnicitySafety-net health systemSociodemographic factors

Identifiers

PMID40234359
PMCPMC13241332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.